6th Edition of Cardiology World Conference | September 15-17, 2025 | Hybrid Event

Dear Conference Visitors:

As the Conference Organizing Committee Member and Keynote Speaker, I am very honored to write this welcome message. 
The current conference, with its overarching theme of “Advancing Heart Health: Breakthroughs in Cardiology”, promises to be a pivotal event for the global cardiology community and aims to address the global challenge posed by cardiovascular disease, a leading cause of approximately 15 million annual fatalities worldwide.

Clearly, the upcoming Cardiology World Conference is an annual collaboration that brings together leading researchers, scientists, clinicians, and industry professionals from cardiovascular health and disease fields around the world. The conference will include outstanding keynote sessions, plenary lectures, invited speeches, research presentations, technical demonstrations, and panel discussions around the world.

All the planned latest cutting-edge presentations and demonstrations will highlight the recent past, current, and future cardiovascular research, explore innovative technologies in cardiovascular disease treatment, and shed light on advancements in managing cardiovascular diseases. Furthermore, all participants including prominent researchers, cardiologists, cardio-thoracic surgeons, healthcare professionals, professors, scientists, students, nurses, and business professionals can gain valuable perspectives from diverse corners of the globe, accelerate breakthroughs in science, trials, and innovations within the realm of cardiology, share their latest research findings, and energize innovative developments and discoveries to unveil breakthroughs and shape future various objectives.

I am very excited to look forward to meeting with you at this fantastic upcoming conference.

6th Edition of Cardiology World Conference | September 15-17, 2025 | London, UK

Dear congress visitors,

It is my honor and pleasure to write some welcome notes to you. Technological innovation, which is characterized by the development and introduction of new surgical procedures, new devices and novel pharmacotherapy, has significantly advanced the cardiothoracic surgery domain. From a historical point of view, technological advancements have really sculpted the field of cardiothoracic surgery, ranging from the development of the heart-lung machine to the creation of left ventricular assist devices and ex-situ cardiac perfusion systems. Such advancements are rooted in basic to translational scientific research and continue to transform the field. Nevertheless, technological innovations come at a price and a clear shift in scientific approach is emerging which is mostly led by the economic burden and the lack of real-time cardiac biofeedback. Our main objective is to determine alternate methods to improve cardiac performance and to determine new ways of getting real-time biofeedback. Within the setting of organ perfusion and cardiac transplantation, we present a novel approach using dynamic biofeedback on cardiac performance combined with innovative therapies not only to improve cardiac function but also prolong graft longevity. In such, within the scope of technological progress, we shift towards a more patient-tailored approach entering the world of precision medicine.

Cardio 2025 | Hybrid Event

It is a pleasure to welcome you to this important scientific event entitled “6th Edition of Cardiology World Conference (Cardio 2025)”. Contemporary medical research contributes strongly to reducing cardiovascular mortality and related major adverse events, such as acute myocardial infarction, heart failure, stroke, or peripheral artery occlusion. Notwithstanding recent advancements, mortality of some types of heart failure is still higher than that of most cancers, which poses a huge unmet medical need to both basic and clinical researchers.

This Conference which brings together physicians and researchers from all over the world will certainly make a significant contribution to scientific exchange and cooperation and, thereby, to novel clinically approved treatment approaches.

I renew the welcome to all of you and wish you all the best in your work.

Cardio 2025 | September 15-17, 2025

Dear delegates,

It gives me immense pleasure to welcome you all to Cardio 2025 that is going to take place in world’s most vibrant city, London in September 2025.
This conference is going to be a grand scientific feast where experts in Cardiology from different parts of the world will share their knowledge, skills and experiences in different aspects of cardiovascular medicine, innovations and research. This is going to be a perfect opportunity to enhance and strengthen your continuous professional development as   well   as nurture your interests in latest developments in Cardiology.  Above all, the conference will serve as a great platform for professional networking and socialization.

Since this conference is in hybrid format, you also have the option to join virtually if circumstances do not allow your physical attendance.

Looking forward to seeing you all in September for a great conference!

Cardio 2025 | London, UK

It is our genuine pleasure to invite you to attend 6th Edition of Cardiology World Confer-ence, which is scheduled to be held in September 15 -17, 2025, in| London, UK.

Cardiovascular diseases are the leading cause of death globally and are escalating in preva-lence in the Globe. Simultaneously treating heart failure and related cardiovascular diseases, using the latest achievements in the area of Personalized & Precision Cardiology integrated with Design-driven Biotech and Translational applications, are excellent starting points to gather distinguished scientists and healthcare professionals to discuss groundbreaking ad-vancements. As well as clinical challenges, in order to find some evidence-based and novel directions to improve our knowledge in this field. Moreover, the upgraded field of cardio-vascular biomarker research is entering a new, exciting era with the introduction of the con-cept of ‘personalized & precision medicine’ in therapeutic treatment guidance. One can ex-pect that the increasing use of cardiovascular biomarkers, accompanying traditional diag-nostic and prognostic measures, for specific cardiovascular diseases, will lead to their almost crucial role in clinical decision making. In this context, the Conference is to provide an inno-vative and comprehensive overview of the latest research developments in cardiovascular medicine, primarily in the areas of personalized cardiology and preventive cardiac surgery. The major goal will be to demonstrate recent development in prevention and prophylaxis, cardiovascular risk prediction based on risk assessment procedures. This approach provides you with an opportunity to ask questions pertinent to your own problems in providing cardi-ac care in your own venue.

The upcoming Heart Global Event will bring together leading researchers, scientists, clini-cians, biodesigners and biotechnologists, and industry professionals from cardiovascular health and disease fields around the world. The Conference will include outstanding keynote sessions, plenary lectures, invited speeches, research presentations, technical demonstra-tions, and panel discussions around the world. So, participants can anticipate a dynamic ex-change of insights, where they can share their latest research findings and gain valuable per-spectives from diverse corners of the Globe. The Event seeks to accelerate breakthroughs in science, trials, and innovations within the realm of cardiology.

The Program has been designed to capture not only the interests of the participants but also to provide them with the state-of-the-art techniques and methods in order to cope with to-day’s challenges in the fight against cardiovascular diseases. So, the Conference will provide enough space for discussion, meetings and workshops in order to allow a close contact be-tween speakers and visitors. Many distinguished cardiologists, cardiac surgeons and scien-tists will take part in this Congress. Papers will be presented in the form of plenary sessions, symposia and posters and will include superb scientific and clinical material that was careful-ly selected by the Review Committee. The Conference will provide the ideal forum to stimu-late ideas and establish collaborations.
It is our greatest pleasure to welcome all of you to join us in this highly educational and in-teractive biennial Conference and collaborate in the global action in reducing the burden of cardiovascular diseases.

We do hope that you will enjoy the Conference and that your interaction with your col-leagues will stimulate a creative exchange of ideas and will be personally rewarding!

6th Edition of Cardiology World Conference | Hybrid Event

Dear distinguished colleagues,

Welcome to the 6th Edition of Cardiology World Conference (Cardio 2025), taking place from September 15-17, 2025 at London, UK and Online. I am honoured  to share the latest advancements in cardiovascular diseases.

Thank you all who will be attending the Conference either virtual or in a person and without your support this event would not be possible.  Another welcome goes to our distinguished speakers from all over the world who will share their up to date scientific knowledge in cardiology.

I do hope that Cardio 2025 will provide full updated scientific knowledge and inspire future ideas and scientific work in the cardiovascular management for the sake of our patients.

Looking forward to our future scientiific cooperation and relationship in the future world cardiology events.

6th Edition of Cardiology World Conference | September 15-17, 2025

Dear Esteemed Colleagues,

It is my pleasure to extend a warm welcome to all attendees of this congress. Chronic kidney disease (CKD) associated with type 2 diabetes remains one of the leading global health challenges, contributing significantly to morbidity and mortality. The need for effective treatment strategies has never been more critical.

The FIDELIO-DKD trial represents a major breakthrough in addressing this urgent issue. By evaluating finerenone, a non-steroidal mineralocorticoid receptor antagonist, this study has demonstrated substantial benefits in reducing the risk of kidney failure, cardiovascular events, and overall mortality in patients with CKD and type 2 diabetes. These findings underscore the dual protective role of finerenone in both renal and cardiovascular health, marking a pivotal advancement in CKD management.

This research not only expands our therapeutic arsenal but also signals a paradigm shift in how we approach CKD treatment in patients with diabetes. Targeting mineralocorticoid receptor activation emerges as a promising strategy to slow disease progression and enhance patient quality of life. The implications of these findings will shape future treatment protocols, improving outcomes for millions worldwide.

I look forward to engaging discussions and collaborative efforts as we explore the future of CKD treatment and its intersection with innovative therapeutic developments.

6th Edition of Cardiology World Conference | London, UK

I am pleased to welcome the participants of the 6th Edition of Cardiology World Conference (Cardio 2025). Traditionally, the scientific program covers a wide range of cardiology issues: from epidemiology and prevention to the use of high technology and artificial intelligence in cardiology. The conference platform brings together scientists and clinicians from different continents and countries of the world. This allows for the exchange of experience and discussions between experts from different medical schools of the world. I am confident that the knowledge gained during the conference will be useful for both researchers and practicing cardiologists.

The abstracts of the reports are presented in the collection of scientific papers. In the future, these papers can also be used to establish contacts with colleagues for cooperation. I would like to express my gratitude to the organizers for their dedicated work and the implementation of this popular project.

I wish good luck and success to my colleagues from different countries of the world.

6th Edition of Cardiology World Conference

Dear Colleagues,

It is my pleasure to welcome you to Cardio 2025, a global gathering of experts dedicated to advancing cardiovascular health. This conference provides a vital platform for sharing groundbreaking research, innovative treatments, and the latest developments in cardiology.

cardiovascular diseases remain a leading global health challenge, and our collective efforts in prevention, diagnosis, and treatment are more crucial than ever. Emerging technologies, including artificial intelligence and precision medicine, are reshaping the field, offering new possibilities for risk assessment and patient care. Through collaboration and knowledge exchange, we can drive progress and improve outcomes for patients worldwide.

I look forward to engaging discussions, insightful presentations, and meaningful connections with all of you. Welcome, and best wishes for a productive and inspiring conference.

5th Edition of Cardiology world Conference | September 05-07, 2024 | Hybrid Event

Welcome! I am thrilled to share the latest advancements in heart failure treatment with you, particularly focusing on sotagliflozin, a groundbreaking therapy offering new hope to patients.

Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor in recent studies have unveiled its significant benefits in treating heart failure, even in patients without diabetes. This dual inhibition mechanism not only lowers blood glucose levels but also has profound effects on heart health.

Clinical trials have demonstrated that sotagliflozin significantly reduces the risk of cardiovascular death and hospitalization due to heart failure. Its ability to promote natriuresis (sodium excretion) and reduce cardiac workload helps alleviate symptoms and improve the quality of life for heart failure patients. Additionally, sotagliflozin's impact on reducing body weight and blood pressure further supports its role in comprehensive heart failure management.

One of the most exciting aspects of sotagliflozin is its effectiveness across a broad spectrum of heart failure patients, including those with preserved and reduced ejection fractions. This versatility makes it a valuable addition to the current treatment options, offering a new therapeutic avenue for patients who may not have responded well to existing therapies.

As we continue to explore and understand the full potential of sotagliflozin, it represents a significant step forward in our fight against heart failure. I am confident that this innovative treatment will play a crucial role in improving patient outcomes and enhancing the quality of care.

Thank you for your attention, and I look forward to the fruitful discussions ahead.

5th Edition of Cardiology World Conference | Hybrid Event

Advanced heart failure is a deadly disease and survival is worse than for breast or prostate cancer. There is a high risk of sudden death. There frequent hospital readmissions and the quality of life is very poor

Heart transplantation at this stage is regarded as the standard in selected patients, however, only a small number of patients have access to donor organs. Early and long-term complications are significant.

For quite some time implantable durable left ventricular assist devices have become a realistic alternative. They are available at any given time. There is no early failure of the transplanted heart and no toxic side effects from chronic immunosuppression. The early and long-term outcomes have become excellent. Innovation of technology will lead to further improvement and will simplify the management and will allow a normal quality of life.

5th Edition of Cardiology World Conference | Cardio 2024

As the Conference Organizing Committee Member and Keynote Speaker, I am very honored to write this welcome message.

The current conference, 5th Edition of Cardiology World Conference, aims to address the global challenge posed by cardiovascular disease, a leading cause of approximately 15 million annual fatalities worldwide.

Clearly, the upcoming Cardiology World Conference is an annual collaboration that brings together leading researchers, scientists, clinicians, and industry professionals from cardiovascular health and disease fields around the world. The conference will include outstanding keynote sessions, plenary lectures, invited speeches, research presentations, technical demonstrations, and panel discussions around the world.

All the planned latest cutting-edge presentations and demonstrations will highlight the recent past, current, and future cardiovascular research, explore innovative technologies in cardiovascular disease treatment, and shed light on advancements in managing cardiovascular diseases. Furthermore, all participants including prominent researchers, cardiologists, cardio-thoracic surgeons, healthcare professionals, professors, scientists, students, nurses, and business professionals can gain valuable perspectives from diverse corners of the globe, accelerate breakthroughs in science, trials, and innovations within the realm of cardiology, share their latest research findings, and energize innovative developments and discoveries to unveil breakthroughs and shape future various objectives.

I am very excited to look forward to meeting with you at this upcoming fantastic conference.

5th Edition of Cardiology World Conference | Madrid, Spain

I am most pleased to invite you to participate in a well-thought out and well planned cardiology Conference “Cardio 2024” to be held in Madrid, Spain during September 5-7, 2024. The Scientific program for this meeting will contain several sessions and invited lectures by some high profile speakers. The conference will focus on discussions and new developments in the area of pathogenesis and therapeutics of heart failure, myocardial infarction, arrhythmias and ischemic heart disease. All residents and fellows as well as academic cardiologists and scientific investigators in the field of cardiovascular medicine will have excellent opportunity of learning new information and improve their skills for the treatment of cardiovascular disease.

5th Edition of Cardiology World Conference

Dear colleagues and participants, as a scientific committee member and keynote speaker, it gives me great honor and pleasure to write this welcome note. Cardiovascular disease remains the main cause of morbidity and mortality globally. With the advancement of genetic and cell biology in life sciences as well as new technologies, numerous cutting-edge research findings are made to improve our understanding of the underlying molecular mechanisms, treatment, and prevention of cardiovascular disease. More excitingly, interactions among vast international researchers are likely to further spark novel ideas, remind potential issues, and find solutions. The Cardiology World Conference, Cardio 2024, that provides a major platform for keynote, plenary talks and poster presentations with both academic and industrial scientific sessions, offers exactly such an outstanding opportunity. I enthusiastically look forward to interacting with you at this exciting international conference for exchanges of ideas and knowledge to advance cardiovascular research and care.

Cardio 2024 | September 05-07, 2024

Welcome to Cardio 2024!

We're excited to introduce Cardio-HART™, an AI-enabled cardiac diagnostic tool designed for point-of-care use. Although AI promises significant advances, they are typically not practical for immediate point-of-care use. This leaves patients waiting with outdated capabilities and relying on referrals to echocardiography, leading to delayed diagnoses and disease progression.

Cardio-HART™ addresses this by using AI to augment and complement ECG, enhancing its diagnostic capabilities. It identifies heart diseases typically diagnosed by echocardiography in secondary care, reducing diagnosis time for heart failure and valve disease from months to same-day as patient presentation. This enables quicker access to treatment and reduces the burden on secondary care.

Cardio-HART™ is to echocardiography what echocardiography is to cardiac-MRI, providing advanced diagnostic capabilities in a simple ECG-like intervention. It decreases unnecessary echocardiograms and eases emergency department pressures by improving point-of-care detection, lowering costs, improving patient outcomes.

Join us at Cardio 2024 to learn more about this innovation.

5th Edition of Cardiology World Conference | September 05-07, 2024

The beginning of the 21st century has gone down in the history of medicine as a time of globalization and socialization of some chronic diseases. Recently, we also faced a pandemic of a viral infection, which primarily affected patients with cardiovascular diseases in adults. Thus, the comorbidity of cardiovascular diseases and other somatic diseases continues to make a large contribution to the development of complications and mortality among adults in most countries. Therefore, the introduction of innovative technologies along with prevention strategies at different levels are an important part of the fight against cardiovascular diseases. The program of the annual conference on cardiology includes current topics on the diagnosis and treatment of cardiac patients. These results of the reports can be useful for both researchers and practitioners. I invite my colleagues to actively participate in the conference.

3rd Edition of Cardiology World Conference | Online

Dear participants of the World Conference on Cardiology.

Cardiovascular disease continues to lead the way in complications and deaths among adults around the world. In developed countries, the incidence rate has decreased, while in developing countries, these rates are somewhat different. Numerous international studies are being carried out to improve the diagnosis, treatment and, most importantly, the prevention of cardiovascular diseases. As data accumulates, international recommendations are updated. It is safe to say that international treatment standards are applied in all countries. But there is a lot of work to be done to introduce innovative technologies in cardiology.

I believe that scientific and educational conferences with the exchange of opinions of specialists from different countries are positively reflected  in the accumulation of experience in the fight against cardiovascular diseases.

I call on my colleagues to actively participate in the work of the World Conference on Cardiology 2022 and wish you success.

Cardiology World Conference, October 24-25, 2019 | Tokyo, Japan

One of the themes of this conference is that of myocardial ischaemia and infarction. At first glance, this would seem to represent purely a repetition of our previous focus on the traditional theme of a common spectrum of cardiovascular disorders driven by the traditional risk factors of hypertension, smoking, diabetes and poor diet, and emerging mainly in middle-aged men. Our therapeutic discussion 30 years ago would have emphasised coronary revascularization above all. However, much has changed. In Western societies, emergence of coronary atheroma-related disease has generally been delayed, if not prevented, while an emerging epidemic threatens the Third World. We have finally learned the importance of inflammation as a key component of the pathogenesis of atherogenesis and myocardial Welcome Message ischaemia, and are beginning to refine our pharmacotherapy to accommodate the recognition of its potential effectiveness and the emergence of “new” forms of acute heart disease which occur mainly in women. I welcome you to the ischaemia/infarction section of the Conference, and trust that you will find our discussions exciting and providing of a better guide to future treatment.

Cardiology World Conference, October 24-25, 2019 | Tokyo, Japan

Dear conference participants and colleagues, I am glad to welcome you to the international conference on cardiology. Cardiovascular diseases are still the main cause of complications and mortality in adults. Moreover, this global trend is observed in both developed and developing countries of the world. Conducted international clinical studies to identify risk factors, primary and secondary prevention of cardiovascular diseases. Annually, the results of major projects on the effectiveness of drugs and new technologies are published. In the 21st century, digital technologies are increasingly used in cardiology. The international conference will highlight various areas in cardiology, which will help in the practical work of specialists. I wish you fruitful work.

Cardiology World Conference, October 24-25, 2019 | Tokyo, Japan

Dear congress visitors, It gives me great pleasure to write a few welcome notes. The field of cardiovascular biomarker research is entering a new, exciting era with the introduction of the concept of ‘personalized medicine’ in therapeutic treatment guidance. With a variety of new cardiovascular biomarkers, and assertions of their respective independent associations with outcome, it becomes increasingly difficult to select the biomarker with the strongest diagnostic as well as prognostic value. One can expect that the increasing use of cardiovascular biomarkers, accompanying traditional diagnostic and prognostic measures, for specific cardiovascular diseases, will lead to their almost crucial role in clinical decision making. However, the search for an ideal biomarker, or set of biomarkers, requires a systematic and rigorous approach to biomarker studies, more emphasis on Welcome Message prospective studies, and use of external validation cohorts. Accomplishment of the previous will lead to improved quality of diagnostic and, even more important, prognostic biomarker research in the future, and will be required if we want to bring this clinically important research field forward.

Cardiology World Conference, October 24-25, 2019 | Tokyo, Japan

Dear congress participants, it is an honor and pleasure to write a few welcome notes. During the last decade, research in cardiovascular field has dramatically increased leading to a substantial improvement in the treatment and the outcome of patients affected with cardiovascular diseases. The main theme of the “Cardiology World Conference” (CWC 2019) will be the “Advances in Cardiology: Research and Innovations”. Latest breaking trials, innovations and hot topics will be discussed in depth during the event involving different fields and specialties contributing to cardiovascular research. Hence, we strongly believe that CWC 2019 will represent a major platform for promoting and advancing cardiology in its dynamic field. We look forward to welcoming you in Tokyo (Japan), for what promises to be an unforgettable Conference. See you there!